PMID- 33425351
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2049-0801 (Print)
IS  - 2049-0801 (Electronic)
IS  - 2049-0801 (Linking)
VI  - 61
DP  - 2021 Jan
TI  - Comparison of fibrin sealants in peripheral vascular surgery: A systematic review 
      and network meta-analysis.
PG  - 161-168
LID - 10.1016/j.amsu.2020.12.003 [doi]
AB  - BACKGROUND: Evidence comparing fibrin sealants (FSs) in surgery are limited. This 
      study evaluated the efficacy and safety of FSs, and manual compression in 
      peripheral vascular surgery. METHODS: A systematic review of randomized trials 
      was conducted in Medline, Embase, and Cochrane databases within the last 15 
      years. Data were available to conduct a network meta-analysis (NMA) in peripheral 
      vascular surgery. Fibrin sealant treatment arms were further broken-down and 
      assessed by clotting time (i.e., 2-min [2C] or 1-min [1C]). The primary efficacy 
      outcome was the proportion of patients achieving hemostasis by 4 min (T4). 
      Treatment-related serious and non-serious adverse events (AEs) were qualitatively 
      assessed. RESULTS: Five studies (n = 693), were included in the NMA. Results 
      predicted VISTASEAL 2C, followed by EVICEL 1C, had the highest probability of 
      achieving T4. Compared with manual compression, significant improvements in T4 
      were found with VISTASEAL 2C (relative risk [RR] = 2.67, 95% CrI: 2.13-3.34), 
      EVICEL 1C (RR = 2.58, 95% CrI: 2.04-3.23), VISTASEAL 1C (RR = 2.00, 95% CrI: 
      1.45-2.65), and TISSEEL 2C (RR = 1.99, 95% CrI: 1.48-2.60). TISSEEL 1C was not 
      significantly different than manual compression (RR = 1.40, 95% CrI: 0.70-2.33). 
      Among FSs, VISTASEAL 2C was associated with a significant improvements in T4 
      compared with VISTASEAL 1C (RR = 1.33, 95% CrI: 1.02-1.82), TISSEEL 2C 
      (RR = 1.34, 95% CrI: 1.05-1.77), and TISSEEL 1C (RR = 1.90, 95% CrI: 1.18-3.74). 
      Treatment-related serious and non-serious AE rates were typically lower than 2%. 
      CONCLUSIONS: In peripheral vascular surgeries, VISTASEAL 2C and EVICEL 1C were 
      shown to have the highest probabilities for achieving rapid hemostasis among the 
      treatments compared. Future studies should expand networks across surgery types 
      as data become available.
CI  - (c) 2020 The Authors.
FAU - Danker Iii, Walter
AU  - Danker Iii W
AD  - Ethicon Inc., Route 22 West, Somerville, NJ, 08876, USA.
FAU - DeAnglis, Ashley
AU  - DeAnglis A
AD  - Ethicon Inc., Route 22 West, Somerville, NJ, 08876, USA.
FAU - Ferko, Nicole
AU  - Ferko N
AD  - CRG-EVERSANA Canada Inc., 204-3228 South Service Road, Burlington, ON, L7N 3H8, 
      Canada.
FAU - Garcia, David
AU  - Garcia D
AD  - CRG-EVERSANA Canada Inc., 204-3228 South Service Road, Burlington, ON, L7N 3H8, 
      Canada.
FAU - Hogan, Andrew
AU  - Hogan A
AD  - CRG-EVERSANA Canada Inc., 204-3228 South Service Road, Burlington, ON, L7N 3H8, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201209
PL  - England
TA  - Ann Med Surg (Lond)
JT  - Annals of medicine and surgery (2012)
JID - 101616869
PMC - PMC7782199
OTO - NOTNLM
OT  - Fibrin tissue adhesive
OT  - Hemostasis
OT  - Network meta-analysis
OT  - Systematic review
OT  - Vascular surgical procedures
COIS- CRG-EVERSANA (N. Ferko, D. Garcia, and A. Hogan) was provided consulting fees 
      from 10.13039/100009933Ethicon Inc., for analysis and development of the 
      manuscript. W. Danker III and A. DeAnglis are employees of Ethicon Inc., the 
      manufacturer for VISTASEAL and EVICEL.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
PMCR- 2020/12/09
CRDT- 2021/01/11 05:39
PHST- 2020/11/20 00:00 [received]
PHST- 2020/12/02 00:00 [accepted]
PHST- 2021/01/11 05:39 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
PHST- 2020/12/09 00:00 [pmc-release]
AID - S2049-0801(20)30520-3 [pii]
AID - 10.1016/j.amsu.2020.12.003 [doi]
PST - epublish
SO  - Ann Med Surg (Lond). 2020 Dec 9;61:161-168. doi: 10.1016/j.amsu.2020.12.003. 
      eCollection 2021 Jan.